Genome-wide expression profiling reveals increased stability and mitochondrial energy metabolism of the human liver cell line HepaRG-CAR.

Constitutive androstane receptor Dedifferentiation Mitochondrial energy metabolism Oxidative stress

Journal

Cytotechnology
ISSN: 0920-9069
Titre abrégé: Cytotechnology
Pays: United States
ID NLM: 8807027

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 25 11 2019
accepted: 24 02 2020
pubmed: 5 3 2020
medline: 5 3 2020
entrez: 5 3 2020
Statut: ppublish

Résumé

Human liver cell line HepaRG is a well-known source of human hepatocyte-like cells which, however, displays limited biotransformation and a tendency to transform after 20 passages. The new HepaRG-CAR cell line overexpressing constitutive androstane receptor (CAR, NR1I3), a regulator of detoxification and energy metabolism outperforms the parental HepaRG cell line in various liver functions. To further characterize this cell line and assess its stability we compared HepaRG-CAR with HepaRG cells at different passages for their expression profile, ammonia and lactate metabolism, bile acid and reactive oxygen species (ROS) production. Transcriptomic profiling of HepaRG-CAR vs. HepaRG early-passage revealed downregulation of hypoxia, glycolysis and proliferation and upregulation of oxidative phosphorylation genesets. In addition CAR overexpression downregulated the mTORC1 signaling pathway, which, as mediator of proliferation and metabolic reprogramming, may play an important role in the establishment of the HepaRG-CAR phenotype. The ammonia and lactate metabolism and bile acid production of HepaRG-CAR cells was stable for 10 additional passages compared to HepaRG cells. Interestingly, bile acid production was 4.5-fold higher in HepaRG-CAR vs. HepaRG cells, whereas lactate and ROS production were 2.7- and 2.0-fold lower, respectively. Principal component analysis showed clustering of HepaRG-CAR (early- and late-passage) and HepaRG early-passage and not with HepaRG late-passage indicating that passaging exerted larger effect on the transcriptional profile of HepaRG than HepaRG-CAR cells. In conclusion, overexpression of CAR in HepaRG cells improves their bile acid production, mitochondrial energy metabolism, and stability, with the latter possibly due to reduced ROS production, resulting in an optimized source of human hepatocytes.

Identifiants

pubmed: 32130581
doi: 10.1007/s10616-020-00384-w
pii: 10.1007/s10616-020-00384-w
pmc: PMC7225227
doi:

Types de publication

Journal Article

Langues

eng

Pagination

377-395

Subventions

Organisme : ZonMw
ID : 114021009

Références

Methods Mol Biol. 2013;987:295-314
pubmed: 23475687
Int J Biochem Cell Biol. 2011 Oct;43(10):1483-9
pubmed: 21726661
Vasc Health Risk Manag. 2006;2(3):213-9
pubmed: 17326328
Free Radic Biol Med. 2009 Aug 15;47(4):344-56
pubmed: 19477268
Biochim Biophys Acta. 2016 Sep;1859(9):1198-1217
pubmed: 27113289
J Lipid Res. 2009 Oct;50(10):1955-66
pubmed: 19346330
In Vitro Cell Dev Biol Anim. 2017 May;53(5):383-405
pubmed: 28374170
Dev Biol. 2013 Dec 15;384(2):155-65
pubmed: 24144921
Compr Physiol. 2013 Jul;3(3):1191-212
pubmed: 23897684
J Hepatol. 2012 Apr;56(4):952-64
pubmed: 22173168
Autophagy. 2007 May-Jun;3(3):238-40
pubmed: 17224623
Arch Toxicol. 2016 Oct;90(10):2513-29
pubmed: 27339419
Int J Artif Organs. 1996 Apr;19(4):245-50
pubmed: 8786176
Arch Toxicol. 2017 Mar;91(3):1385-1400
pubmed: 27344343
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
J Hepatol. 2015 Oct;63(4):934-42
pubmed: 26022688
Arch Toxicol. 2017 Jan;91(1):439-452
pubmed: 27039104
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3423-30
pubmed: 27247419
Cancer Res. 2007 May 1;67(9):4337-45
pubmed: 17483347
Hepatology. 2009 Jun;49(6):2031-43
pubmed: 19274752
J Biomol Tech. 2018 Jul;29(2):25-38
pubmed: 29805321
PLoS One. 2012;7(6):e38778
pubmed: 22719943
Biochem J. 2012 Jan 15;441(2):523-40
pubmed: 22187934
PLoS One. 2018 Apr 19;13(4):e0193664
pubmed: 29672606
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15655-60
pubmed: 12432097
Gerontology. 2018;64(2):127-134
pubmed: 29190625
Expert Opin Biol Ther. 2014 Dec;14(12):1745-60
pubmed: 25366164
Liver Transpl. 2001 Jan;7(1):2-10
pubmed: 11150414
Free Radic Biol Med. 2015 Oct;87:84-97
pubmed: 26117330
Antioxid Redox Signal. 2013 Feb 1;18(4):412-23
pubmed: 22867017
Oxid Med Cell Longev. 2016;2016:3565127
pubmed: 27247702
Mol Pharmacol. 2014 Feb;85(2):249-60
pubmed: 24252946
Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):909-20
pubmed: 22568886
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
PLoS One. 2014 Feb 03;9(2):e88011
pubmed: 24498423
J Biol Chem. 2015 Jan 23;290(4):2405-18
pubmed: 25433341
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
J Biol Chem. 2003 Aug 8;278(32):29667-75
pubmed: 12777400
J Proteome Res. 2013 Jun 7;12(6):2732-41
pubmed: 23641669
Nucleic Acids Res. 2018 Sep 19;46(16):8385-8403
pubmed: 30102401
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
Mitochondrion. 2018 Mar;39:30-42
pubmed: 28844938
Cell Biol Toxicol. 2017 Aug;33(4):407-421
pubmed: 28144825
Lancet. 1993 Oct 23;342(8878):1050-1
pubmed: 8105280
Liver Res. 2017 Jun;1(1):3-9
pubmed: 29104811
Drug Metab Dispos. 2017 Jan;45(1):56-67
pubmed: 27780834
Acta Pharmacol Sin. 2015 Jan;36(1):62-70
pubmed: 25500869
Cell Transplant. 2006;15(5):423-33
pubmed: 16970284
Curr Drug Metab. 2006 Aug;7(6):629-60
pubmed: 16918317
Hepatology. 2016 Nov;64(5):1743-1756
pubmed: 27532775
Physiol Genomics. 2001 Dec 21;7(2):97-104
pubmed: 11773596
Biochem Pharmacol. 2018 Sep;155:124-140
pubmed: 29953844
Drug Metab Dispos. 2013 Mar;41(3):562-7
pubmed: 23238784
Int J Mol Sci. 2018 Oct 21;19(10):
pubmed: 30347859
Anal Biochem. 2005 May 15;340(2):376-9
pubmed: 15840513
Drug Metab Dispos. 2007 Oct;35(10):1806-15
pubmed: 17627975
Interdiscip Top Gerontol. 2014;39:86-107
pubmed: 24862016
Nature. 2011 Jan 13;469(7329):221-5
pubmed: 21124315
Biochem Soc Trans. 2003 Jun;31(Pt 3):497-501
pubmed: 12773143
Int J Biochem Cell Biol. 2013 Aug;45(8):1860-8
pubmed: 23770120
Drug Metab Dispos. 2017 Apr;45(4):419-429
pubmed: 28137721
Hepatology. 2010 Dec;52(6):2127-36
pubmed: 20979052
Int J Mol Sci. 2015 Nov 02;16(11):26087-124
pubmed: 26540040
Mol Pharmacol. 2018 Jul;94(1):749-759
pubmed: 29691280
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
J Gastroenterol. 2005 Mar;40(3):320-1
pubmed: 15830297

Auteurs

Aziza A A Adam (AAA)

Tytgat Institute for Liver and Intestinal Research, AG&M, Amsterdam UMC, University of Amsterdam, Meibergdreef 69-71, 1105 BK, Amsterdam, The Netherlands.

Aldo Jongejan (A)

Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Perry D Moerland (PD)

Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Vincent A van der Mark (VA)

Tytgat Institute for Liver and Intestinal Research, AG&M, Amsterdam UMC, University of Amsterdam, Meibergdreef 69-71, 1105 BK, Amsterdam, The Netherlands.
Surgical Laboratory, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Ronald P Oude Elferink (RP)

Tytgat Institute for Liver and Intestinal Research, AG&M, Amsterdam UMC, University of Amsterdam, Meibergdreef 69-71, 1105 BK, Amsterdam, The Netherlands.

Robert A F M Chamuleau (RAFM)

Tytgat Institute for Liver and Intestinal Research, AG&M, Amsterdam UMC, University of Amsterdam, Meibergdreef 69-71, 1105 BK, Amsterdam, The Netherlands.

Ruurdtje Hoekstra (R)

Tytgat Institute for Liver and Intestinal Research, AG&M, Amsterdam UMC, University of Amsterdam, Meibergdreef 69-71, 1105 BK, Amsterdam, The Netherlands. r.hoekstra@amc.uva.nl.
Surgical Laboratory, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. r.hoekstra@amc.uva.nl.

Classifications MeSH